New hope for kids with tough leukemia: chemo combo trial launches

NCT ID NCT06466395

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a combination of two drugs—Hyper-CVAD chemotherapy and venetoclax—in 22 children and young adults whose leukemia has returned or not responded to treatment. The main goal is to find a safe dose and monitor side effects. If the combination proves safe, it could lead to larger studies to see if it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Venetoclax and Hyper-CVAD chemotherapy
What this could lead to
If successful, this could point toward a new treatment option for children with hard-to-treat leukemias that have come back or not responded to standard therapy.
What could go wrong
This is an early phase 1 trial with only 22 participants, focused on finding a safe dose. It is too small and early to know if the combination will work better than existing treatments, and there are risks of serious side effects from the chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BI-PHENOTYPIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.